Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum (II) and Other Antitumor Agents by Inhibitors of Enzymes Involved in Growth Factor Signal-Transduction

  • Hans H. Grunicke
  • Johann Hofmann
  • Karl Maly
  • Hermann Oberhuber
  • Florian Uberall
  • Alexander Egle
  • Lars Demuth

Abstract

Progress in our understanding of the biochemical basis of malignant growth has led to the identification of new targets in tumor chemotherapy. In many cases the uncontrolled, autonomous growth of transformed cells has been shown to be caused by one of the following mechanisms: (1) autrocrine production of growth factors; (2) expression of constitutively active growth factor receptors; (3) constitutive activation of elements of growth factor signal transduction1–3. In view of these findings, novel strategies for tumor chemotherapy have been developed including growth factor antagonists4 growth factor receptor blockers5 and inhibitors of enzymes or ion channels involved in intracellular mitogenic signal transfer. Approaches to interfere with growth factor signal transduction include studies on inhibitors of phospholipase C, protein tyrosine kinases, protein kinase C, Na+/H+-antiporter and Ca2+ antagonists6,7. A variety of compounds which were developed along these lines of research exhibit remarkable antitumor activity, some of them are less toxic than established, currently employed antitumor agents. With regard to these low toxicity compounds it seemed intriguing to investigate whether their growth inhibitory activity could be combined with the growth inhibition by established antitumor agents. In such a mixture, the combination of the growth inhibitory effects of the components may exhibit an additive or synergistic behaviour. This could be exploited for a less toxic and/or more effective treatment protocol.

Keywords

Depression Tamoxifen Benzoquinone Verapamil Neuroblastoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    R.A. Weinberg, The action of oncogenes in the cytoplasm and nucleus, Science 230:770 (1985).PubMedCrossRefGoogle Scholar
  2. 2.
    A.S. Goustin, E.B. Leof, G.D. Shipley, and H. Moses, Growth factors and cancer, Cancer Res. 46:1015 (1986).PubMedGoogle Scholar
  3. 3.
    C.H. Heldin and B. Westermark, Growth factors as transforming proteins, Eur. J. Biochem, 184:487 (1989).PubMedCrossRefGoogle Scholar
  4. 4.
    J.E. Layton, D.B. Scanlon, C. Soveny, and G. Morstyn, Effects of bombesin antagonists on the growth of small cell lung cancer cells in vitro, Cancer Res. 48:4783 (1988).PubMedGoogle Scholar
  5. 5.
    A.T. Van Oosterom, D.A. De Smedt, L.J. Denis, E.A. de Bruijn, and C. Mahler, Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated desease, Eur. J. Cancer 26:422 (1990).PubMedCrossRefGoogle Scholar
  6. 6.
    T.R. Tritton and J.A. Hickmann, How to kill cancer cells: Membranes and cell signalling as targets in cancer chemotherapy, Cancer Cells 2:95 (1990).PubMedGoogle Scholar
  7. 7.
    H. Grunicke, Cell membrane as a target for cancer chemotherapy, Eur. J. Cancer in press.Google Scholar
  8. 8.
    U. Kikkawa, A. Kishimoto, and Y. Nishizuka, The protein kinase C family, Heterogeneity and its implications, Ann. Rev. Biochem. 58:31 (1989).PubMedCrossRefGoogle Scholar
  9. 9.
    C.J. Marshall, A.C. Lloyd, J.D.H. Morris, H. Paterson, B. Price, and A. Hall, Signal transduction by p21ras, Int. J. Cancer Suppl. 4: 29 (1989).PubMedCrossRefGoogle Scholar
  10. 10.
    J. Hofmann, F. Überall, L. Posch, K. Maly, D.B.J. Herrmann, and H. Grunicke, Synergistic enhancement of the antiproliferative activity of cis diammine dichloroplatinum (II) by the ether lipid analogue BM 41440 an inhibitor of protein kinase C, Lipids 24:312 (1989).PubMedCrossRefGoogle Scholar
  11. 11.
    M. Shoji, R. Raynor, W.E. Berdel, W.R. Vogler, and J.F. Kuo, Effects of thioether phospholipid BM41440 on protein kinase C and phorbol ester induced differentiation of human leukemia HL60 and KG-lcells, Cancer Res. 48:6669 (1989).Google Scholar
  12. 12.
    B. Zheng, K. Oishi, M. Shoji, H. Eibl, W.E. Berdel, J. Hajdo, W.R. Vogler, and J.F. Kuo, Inhibition of protein kinase C (sodium plus potassium)-activated adenosine triphosphatase and sodium pump by synthetic phospholipid analogues, Cancer Res. 50:3025 (1990).PubMedGoogle Scholar
  13. 13.
    F. Überall, H. Oberhuber, K. Maly, J. Zaknun, L. Demuth, and H.H. Grunicke, Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity, Cancer Res. 51 in press.Google Scholar
  14. 14.
    J. Hofmann, W. Doppler, H. Jakob, K. Maly, L. Posch, F. Überall, and H.H. Grunicke, Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C, Int. J. Cancer 42:382 (1988).PubMedCrossRefGoogle Scholar
  15. 15.
    K. Maly, F. Überall, H. Loferer, W. Doppler, H. Oberhuber, B. Groner, and H.H. Grunicke, Ha-ras activates the Na+/H+-antiporter by a protein kinase C independent mechanism, J. Biol. Chem. 264:11839 (1989).PubMedGoogle Scholar
  16. 16.
    T.M. Fisch, R. Prywes, and R.G. Roeder, C-fos sequences necessary for basal expression and induction by epidermal growth factor, 12-O-tetradecanoyl phorbol-13-acetate and the calcium ionophor, Mol. Cell. Biol. 7:3490 (1987).PubMedGoogle Scholar
  17. 17.
    T.M. Fisch, R. Prywes, and R.G. Roeder, An AP-1 binding site in the fos gene can mediate induction by epidermal growth factor and 12-0-tetradecanoyl phorbol-13-acetate, Mol. Cell. Biol. 9:1327 (1989).PubMedGoogle Scholar
  18. 18.
    T.C. Chou and P. Talalay, Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Advanc. Enzyme Regul. 22:27 (1984).CrossRefGoogle Scholar
  19. 19.
    J. Hofmann, H. Fiebig, B.R. Winterhaiter, D.P. Berger, and H.H. Grunicke, Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum (II) by quercetin, Int. J. Cancer 45:536 (1990).PubMedCrossRefGoogle Scholar
  20. 20.
    H. Grunicke, W. Doppler, J. Hofmann, H. Lindner, K. Maly, H. Oberhuber, H. Ringsdorf, and J.J. Roberts, Plasma membrane as target of alkylating agents, Advanc. Enzyme Regul. 24:247 (1986).CrossRefGoogle Scholar
  21. 21.
    H. Grunicke, F. Hirsch, H. Wolf, U. Bauer, and G. Kiefer, Selective inhibition of thymidine transport at low doses of the alkylating agent trisethyleneiminobenzoquinone (Trenimon), Exptl. Cell. Res. 90:357 (1975).PubMedCrossRefGoogle Scholar
  22. 22.
    M. Ihlenfeldt, G. Gantner, H. Harrer, B. Puschendorf, H. Putzer, and H. Grunicke, Interaction of the alkylating antitumor agent 2,3,5-tris(ethylenimino) benzoquinone with the plasma membrane of Ehrlich ascites tumor cells, Cancer Res. 41:289 (1981).PubMedGoogle Scholar
  23. 23.
    W. Doppler, J. Hofmann, H. Oberhuber, K. Maly, and H. H. Grunicke, N-mustard interference with potassium transport systems in Ehrlich ascites tumor cells, J. Cancer Res. Clin. Oncol. 110:35 (1985).PubMedCrossRefGoogle Scholar
  24. 24.
    M.A. Baxter, S.B. Chawala, J.A. Hickman, and G.E. Spurgin, The effect of nitrogen mustard (HN2) on activities of the plasma membrane of PC6A mouse plasmacytoma cells, Biochem. Pharmacol. 31:1773 (1982).PubMedCrossRefGoogle Scholar
  25. 25.
    M.Meyer, K.Maly, F. Überall, J. Hoflacher, and H.H. Grunicke, Stimulation of K+ transport by Ha-ras, J. Biol. Chem. in press.Google Scholar
  26. 26.
    B. Hamel, S. Malachowsky, L. Vancamp, and E.J. McGroarty, The effect of CaCl2 and verapamil on the binding of cis platin to cultures of normal and transformed human fibroblasts, Cancer Biochem. Biophys. 11:155 (1990).PubMedGoogle Scholar
  27. 27.
    P.M. Vassilev, M.P. Kanazirska, J.L. Charamella, N.V. Dimitrov, and H.T. Tien, Changes in calcium channel activity in membranes from cis-diamminedichloroplatinum II-resistant and sensitive L1210 cells, Cancer Res. 47:519 (1987).PubMedGoogle Scholar
  28. 28.
    S. Shionoya, A. Ly, and K.J. Scanlon, Properties of aminoacids transport systems in K 562 cells sensitive and resistant to cis-diamminedichloroplatinum (II), Cancer Res. 46:3445 (1986).PubMedGoogle Scholar
  29. 29.
    H. Glossmann, P. Presek, and E. Eigenbrodt, Quercetin inhibits tyrosine phosphorylation by the cyclic nucleotide-independent transforming protein kinase pp60src. Arch. Pharmakol. 312:100 (1981).CrossRefGoogle Scholar
  30. 30.
    C.D. Smith, J.F. Glickman, and K.J. Chang, The antiproliferative effects of staurosporine are not exclusively mediated by inhibition of protein kinase C, Biochem. Biophys. Res. Commun. 156:1250 (1988).PubMedCrossRefGoogle Scholar
  31. 31.
    M.J. Seewald, R.A. Olsen, I. Seghai, D.C. Melders, E.J. Modest, and G. Powis, Inhibition of growth factor independet inositol phosphate Ca2+ signaling by antitumor ether lipid analogues, Cancer Res. 50:4458 (1990).PubMedGoogle Scholar
  32. 32.
    H. Ikeda, G. Nakano, K. Nagashima, K. Sakamoto, N. Harasawa, T. Kitamura, T. Nakamura, and Y. Nagamachi, Verapamil enhancement of antitumor effect of cis-diammine dichloroplatinum (II) in nude mouse-grown human neuroblastoma, Cancer Res. 47:231 (1989).Google Scholar
  33. 33.
    J. Onoda, K.K. Nelson, J.D. Taylor, and K.V. Honn, Cis platin and nifedipine: Synergistic antitumor effects against an inherently cisplatin-resistant tumor, Cancer Lett, 40:390(1988).CrossRefGoogle Scholar
  34. 34.
    J.M. Onoda, K.K. Nelson, J.D. Taylor, and K.V. Honn, In vivo characterisation of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloro-platinum (II), Cancer Res, 49:2844 (1989).PubMedGoogle Scholar
  35. 35.
    T. Mori, Y. Takai, R. Minakuchi, B. Yu, and Y. Nishizuka, Inhibitory action of chlorpromazine, dibucaine and other phospholipid-interacting drugs on calcium-activated phospholipid-dependent protein kinase, J. Biol. Chem. 255:8378 (1980).PubMedGoogle Scholar
  36. 36.
    B.C. Wise and J.F. Kuo, Mode of inhibition of acylcarnitines, adriamycin and trifluoperazine of cardiac phospholipid-sensitive calcium dependent protein kinase, Biochem. Pharmacol. 32:1259 (1983).PubMedCrossRefGoogle Scholar
  37. 37.
    K. Satyamoorty and J. Perchellet, Modulation by adriamycin, daunomycin, verapamil and trifluoperazine of the biochemical processes linked to mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate, Cancer Res. 49:5364 (1989).Google Scholar
  38. 38.
    S. Isonishi, P. Andrews, and St B. Howell, Increase sensitivity to cis-diamminedichlorplatinum (II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol-13-acetate, J. Biol. Chem. 265:3623 (1990).PubMedGoogle Scholar
  39. 39.
    J.M. Darbon, H. Valette, S. Jozan, M. Issandou, and F. Bayard, Dissociation between protein kinase C content and biological responsiveness to phorbol esters in tumor promotion-sensitive (MCF-7) and resistant (RPh-4) cells, Biochem. Pharmacol. 40:1785 (1990).PubMedCrossRefGoogle Scholar
  40. 40.
    P.M. Blumberg, In vitro studies on the mode of action of the phorbol esters, potent tumor promoters, CRC Crit. Rev. Toxicol. 8:153 (1980).CrossRefGoogle Scholar
  41. 41.
    P.M. Choi, K.M.T. Wong, and I.B. Weinstein, Overexpression of protein kinase C in HT 29 colon cancer cells causes growth inhibition and tumor suppression, Mol. Cell. Biol. 10:4650 (1990).PubMedGoogle Scholar
  42. 42.
    S. Jaken, Measurement of phorbol ester receptors in intact cells and subcellular fractions, Meth. Enzymol. 141:275 (1987).PubMedCrossRefGoogle Scholar
  43. 43.
    N.H. Khan, V. Quemener, and J.Ph. Moulinoux, Phorbol esters augment spermidine transport without protein kinase C activation, Biochem. Pharmacol. 40:R1 (1990).PubMedCrossRefGoogle Scholar
  44. 44.
    R.L. Fine, J. Patel, and B.A. Chabner, Phorbol esters induce multidrug resistance in human breast cancer cells, Proc. Natl. Acad. Sci. (US) 85:582 (1988).CrossRefGoogle Scholar
  45. 45.
    T.C. Chambers, E.M. McAvoy, J.W. Jacobs, and G. Eilon, Protein kinase C phosphorylates p-glycoprotein in multidrug resistant human KB carcinoma cells, J. Biol. Chem. 265:7679 (1990).PubMedGoogle Scholar
  46. 46.
    S.T. Palayoor, J.M. Stein, and W.N. Hait, Inhibition of protein kinase C by antineoplastic agents: Implications for drug resistance, Biochem. Biophys. Res. Commun. 148:718 (1987).PubMedCrossRefGoogle Scholar
  47. 47.
    H. König, H. Ponta, U. Rahmsdorf, M. Büscher, A. Schönthal, H.J. Rahmsdorf, and P. Herrlich, Autoregulation of fos: the dyad symmetry element as the major target of repression, EMBO J. 8:2559 (1989).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Hans H. Grunicke
    • 1
  • Johann Hofmann
    • 1
  • Karl Maly
    • 1
  • Hermann Oberhuber
    • 1
  • Florian Uberall
    • 1
  • Alexander Egle
    • 1
  • Lars Demuth
    • 1
  1. 1.Institute of Medical Chemistry and BiochemistryUniversity of InnsbruckInnsbruckAustria

Personalised recommendations